ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

 PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24

ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids

 ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that they will present at ESHRE Virtual 36th Annual Meeting, taking place July  5-8, 2020.

ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020

 ObsEva SA (NASDAQ: OBSV / SIX: OBSN - a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy), and Yuyuan BioScience Technology (“Yuyuan”) today announced that Yuyuan has submitted a pre-IND meeting request for nolasiban to the Center for Drug Evaluation at the Chinese National Medical Products Administration (NMPA).

ObsEva and Yuyuan BioScience Technology Announce Submission of the  Pre-IND Dossier for Nolasiban with the Chinese NMPA

Geneva, Switzerland and Boston, MA – June 9, 2020  - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that shareholders approved all Board proposals at its 2020 Annual General Meeting held on June 9, 2020.

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2020 Annual General Meeting held on June 9, 2020

GENEVA, Switzerland and BOSTON, MA (June 4, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported publication in the journal Fertility and Sterility of “ Gonadotropin-releasing Hormone Antagonist (linzagolix): a New Therapy for Uterine Adenomyosis,” a case report from a pilot study assessing the use of linzagolix for the treatment of uterine adenomyosis.

ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis

ObsEva Has A Promising Candidate For An Unmet Need - Behind The Idea

 ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the quarter ended March 31, 2020 and provided a business update.

ObsEva Announces First Quarter 2020 Financial Results and Business Update

ObsEva (OBSV) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

How ObsEva (OBSV) Stock Stands Out in a Strong Industry

 Geneva, Switzerland and Boston, MA – April 6, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced the nomination of Fabien de Ladonchamps, Vice President Corporate Affairs & Finance, as interim Chief Financial Officer and member of the Executive Committee, following the resignation of Tim Adams, effective close of business April 10, 2020.

ObsEva SA Announces New Interim Chief Financial Officer

 GENEVA, Switzerland and BOSTON, MA (March 23, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today provided an update regarding the impact of the COVID-19 pandemic on  its clinical development programs.

ObsEva Provides Update Related to COVID-19 Pandemic

ObsEva's (OBSV) CEO Ernest Loumaye on Q4 2019 Results - Earnings Call Transcript

Wall Street analysts recommend increasing holdings in EQT Corporation (NYSE:EQT) and ObsEva SA (NASDAQ:OBSV), even though their share prices have dropped more than 59% in the past year through Jan.

Analysts Suggest Picking Up These 2 Falling Knives: EQT & OBSV

Shares of ObsEva  gained 22% in premarket trading on the news that the company' s experimental treatment for women with uterine fibroids met its primary and secondary endpoints in a Phase 3 trial. The drug, linzagolix, is meant to reduce heavy bleeding in those patients.

ObsEva shares rise on new data about fibroid treatment

ObsEva has been struggling lately, but the selling pressure may be coming to an end soon.

ObsEva Sees Hammer Chart Pattern: Time to Buy?

ObsEva SA has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

ObsEva Enters Oversold Territory

ObsEva SA (OBSV) delivered earnings and revenue surprises of 23.17% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

ObsEva SA (OBSV) Reports Q3 Loss, Misses Revenue Estimates

 ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that the Phase 3 clinical trial results from its European confirmatory study of nolasiban (IMPLANT 4) in women undergoing embryo transfer (ET) following in-vitro fertilization (IVF) did not meet the primary endpoint of an increase in ongoing pregnancy rate at 10 weeks, (39.1 % placebo vs 40.5 % nolasiban) (p = 0.745). Nolasiban was well tolerated. All subjects will continue to be followed up to delivery and infant development will be assessed up to 6 months.

Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint

 Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that the U.S. Food and Drug Administration (FDA) has allowed the Company to begin enrolling patients in IMPLANT 3, the U.S pivotal Phase 3 clinical trial of nolasiban in women undergoing embryo transfer (ET) following in-vitro fertilization (IVF).

ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF

Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of endometriosis-association pain and heavy bleeding from uterine fibroids while maintaining bone health

ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy

Geneva, Switzerland and Boston, MA – October 9, 2019- ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss  clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced  the presentation of new data for its lead compounds, nolasiban and linzagolix, at the 75th American Society of Reproductive Medicine (ASRM) Scientific Congress & Expo taking place in Philadelphia (PA) from October 12 -16, 2019.

ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA

Geneva, Switzerland and Boston, MA – September 27, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that Company Management will be participating in the Cantor Global Healthcare Conference taking place October 2-4, 2019 in New York City. ObsEva will present on Friday, October 4 at 7:45 a.m. Eastern time (ET).

ObsEva SA to Participate in Cantor Global  Healthcare Conference October  2-4, 2019

Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, announce today changes to the composition of its Executive Committee following approval by its Board of Directors

ObsEva announces new composition of its Executive Committee

Results show decreased uterine contractions, increased endometrial blood flow and gene expression relevant for uterine receptivity to implantation

ObsEva Reports New Clinical Evidence of Nolasiban Mechanism of Action, Supporting Its Potential to Increase Live Birth Rate  Following Embryo Transfer in IVF

Geneva, Switzerland and Boston, MA – August 30, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that Company Management will be participating  two upcoming investor conferences.

ObsEva SA to Participate in Upcoming Investor Conferences

ObsEva SA (OBSV) CEO Ernest Loumaye on Q2 2019 Results - Earnings Call Transcript

News for ObsEva Stock (OBSV)